However, while both MEK and BRAF inhibitors have been associated with high overall response rates in histiocytic neoplasms [13,14], immediate toxicity, the potential for delayed toxicity, and cost become increasingly important factors as continuous therapy appears to be necessary for a durable response [13, 24]. The gene discussed is MAP2K7; the disease is histiocytic neoplasm.